№ lp_1_2_16626
File format: docx
Character count: 2045
File size: 16 KB
Press release announcing the recognition of an executive from XX ORGANIZATION as part of the Constellation Research 2026 Business Transformation 150 list for leadership in driving digital innovation and transformation.
Year:
2025
Region / City:
Palo Alto, California
Topic:
Business Transformation, Digital Leadership, Artificial Intelligence
Document Type:
Press Release
Organization:
XX ORGANIZATION
Author:
Constellation Research
Target Audience:
Business Executives, Industry Leaders, Technology Analysts
Effective Date:
June 17, 2025
Date of Changes:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
Lunar South Pole
Topic:
Lunar Communications and Navigation Systems
Document Type:
Technical Report
Organization:
NASA GSFC
Author:
Grant Ryden, Michael Volle
Target Audience:
Researchers and engineers involved in lunar missions and navigation
Period of Validity:
Not specified
Approval Date:
Not specified
Revision Date:
Not specified
Year:
2025
Region / City:
Ispra, Italy
Topic:
Land Surface Imaging, Earth Observation
Document Type:
Meeting Agenda
Organization / Institution:
European Commission Joint Research Centre (EC-JRC)
Author:
CEOS Virtual Constellation for Land Surface Imaging
Target Audience:
CEOS members, Earth Observation stakeholders
Period of validity:
2-5 September 2025
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2026
Region / City:
United States
Topic:
Broadband, Satellite Communications
Document Type:
Statement
Organization:
Federal Communications Commission (FCC)
Author:
Brendan Carr
Target Audience:
Policymakers, Telecommunications Industry Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Constellation:
Sagittarius
Alternative Names:
人馬座; The Archer
Astronomical System:
Milky Way
Historical Source:
Ptolemy
Earliest Recorded Reference:
Ancient Babylonian astronomical compendium (circa 1000 BCE)
Mythological Associations:
Greek mythology; Crotus; Roman mythology (Pluto)
Notable Stars:
Delta Sagittarii (Kaus Media); Epsilon Sagittarii (Kaus Australis); Sigma Sagittarii (Nunki)
Galaxy Center Location:
Direction of Sagittarius
Astronomical Object:
Pluto
Discoverer of Pluto:
Clyde Tombaugh
Discovery Year of Pluto:
1930
Reclassification Authority:
International Astronomical Union
Reclassification Year:
2006
Dwarf Planet Designation:
(134340) Pluto
IAU Criteria Reference Year:
2006
Other Recognized Dwarf Planets:
Ceres; Eris; Haumea; Makemake
Kuiper Belt Region:
Beyond Neptune
Pluto Orbital Period:
248 years
Pluto Diameter:
Approximately 2300 km
Known Moons of Pluto:
Five (including Charon)
Pluto Moon Discoverer:
James Christy
Space Mission Mentioned:
New Horizons
Document Type:
Astronomical reference text
Year:
2023
Region / City:
Atlanta, GA
Theme:
Astronomy
Document Type:
Educational Project
Institution:
Not specified
Author:
Not specified
Target Audience:
Students
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Year
Context:
Detailed description of the Centaurus constellation, its stars, and associated mythology.
Year:
2025
Note:
Region / City
Subject:
Corporate Governance
Document Type:
Corporate Governance Principles
Organization:
Constellation Energy Corporation
Author:
Corporate Governance Committee
Target Audience:
Board of Directors, Senior Management, Shareholders
Effective Date:
April 11, 2025
Date of Adoption:
April 11, 2025
Year:
2026
Region / City:
Northern Hemisphere
Topic:
Astronomy / Constellations
Document Type:
Educational Activity
Organization / Institution:
NIRCam E/PO Team
Author:
Larry and Nancy Lebofsky
Target Audience:
Girl Scouts, Students (Elementary and Middle School)
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2025-2026
Region / city:
Boston
Topic:
Medical Education
Document Type:
Course Information
Institution / Organization:
Chobanian & Avedisian School of Medicine
Author:
Not specified
Target Audience:
Medical students
Period of validity:
AY 2025-2026
Approval Date:
Not specified
Revision Date:
Not specified
Year:
2024
Region / city:
Australia
Topic:
Pharmacological treatment
Document type:
Pharmaceutical submission
Agency / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Unknown
Target audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval date:
23 December 2024
Date of amendments:
Not specified
Note:
Year
Background:
The submission requested a General Schedule Authority Required (Telephone/Online) listing of a new form of adrenaline (epinephrine) acid tartrate 150 micrograms/0.15 mL autoinjector (AI) (Jext® Junior (Jr)) and 300 micrograms/0.3 mL AI (Jext®) under the same circumstances as the currently listed adrenaline (epinephrine) 150 microgram/0.3 mL AI (EpiPen® Jr and Anapen® Jr 150) and 300 microgram/0.3 mL AI (EpiPen® and Anapen® 300).
Year:
2024
Region / City:
N/A
Topic:
Digest submission guidelines for Evolution Conference
Document Type:
Academic submission guidelines
Organization / Institution:
Evolution Conference Technical Program Committee
Author:
N/A
Target Audience:
Authors submitting to the Evolution Conference
Period of validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2021
Region / city:
N/A
Topic:
Academic Paper Formatting Guidelines
Document Type:
Conference Digest
Institution:
IEMDC Technical Program Committee
Author:
A. Jones, C. Maxwell, B. Smith
Target Audience:
Researchers, Academics, Conference Reviewers
Effective Period:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Year:
2023
Region:
Wales
Country:
United Kingdom
Healthcare system:
NHS Wales
Document type:
Patient Group Direction
Medicine:
Fluconazole 150 mg capsule
Clinical indication:
Vulvovaginal candidiasis
Service framework:
Clinical Community Pharmacy Service
Service component:
Common Ailment Service
Authoring body:
Welsh Medicines Advice Service
Approving body:
Community Pharmacy Clinical Advisory Group
Target professionals:
Registered community pharmacists
Legal basis:
Human Medicines Regulations 2012
Operational start date:
1 July 2023
Review date:
31 March 2026
Expiry date:
30 June 2026
Version:
1.0
Approval date:
3 July 2023
Source type:
Regulatory and clinical governance document
Year:
2022
Region / City:
Johnson City, Tennessee
Theme:
Academic Research
Document Type:
Thesis/Dissertation
Institution:
East Tennessee State University
Author:
Your Name
Target Audience:
Scholars, Researchers
Period of Action:
2022-2023
Date of Approval:
[Date not provided]
Date of Changes:
[Date not provided]
Year:
2014
Country:
Australia
City:
Sydney
Industry:
Software / Technology
Subject:
Financial statement projections and investment analysis
Document Type:
Case Study
Company:
Atlassian
Products:
JIRA; Confluence; Dev Tools
Revenue (Most Recent Fiscal Year):
$200 million AUD
Revenue Growth:
25% CAGR over the past 3 years
Investment:
$150 million USD
Investor:
T. Rowe Price
Previous Investment:
$60 million USD by Accel Partners at $400 million valuation
Ownership Structure:
Secondary share sale by employees; no new shares issued
Tax Rate Applied:
30% Australian corporate tax rate
Projection Period:
5 years
Financial Statements Covered:
Income Statement; Balance Sheet; Cash Flow Statement
Target Audience:
Growth equity analysts
Year:
2001
Region / City:
Illinois
Theme:
Legal and Regulatory Amendments
Document Type:
Regulation
Organization / Institution:
State of Illinois
Author:
Illinois Legislature
Target Audience:
Public and Legal Professionals
Period of Effect:
December 1, 2001–July 29, 2024
Approval Date:
December 1, 2001
Amendment Date:
August 30, 2023
Contextual Description:
A regulatory document outlining the adoption and amendments of a specific rule, detailing the various effective dates and emergency amendments over time.
Country:
Republic of the Philippines
City:
Cebu City
Place of Execution:
City of Laguna
Document Type:
Contract of Lease
Parties:
Ross Geller (Lessor); Phoebe Buffay (Lessee)
Property Description:
Unit 150, Central Perk, AS Fortuna St., Banilad, Cebu City
Use of Premises:
Commercial purposes only
Lease Term:
One (1) year
Lease Period:
June 1, 2024 to May 31, 2025
Monthly Rental Rate:
Thirty Thousand Pesos (P30,000)
Security Deposit:
Ninety Thousand Pesos (P90,000) equivalent to three (3) months’ rent
Default Provision:
Termination, ejectment, padlocking, and forfeiture of deposits upon non-payment
Sublease Condition:
Prohibited without written approval of the Lessor
Utilities Responsibility:
Payable by the Lessee
Force Majeure Clause:
Termination without compensation upon substantial destruction or damage
Judicial Relief Clause:
Attorney’s fees equivalent to 100% of claim, not less than P50,000.00
Notarial Act:
Acknowledged before a Notary Public
Series:
2024
Year:
2021
Category:
Category 4 Submission
Type of Document:
Submission for PBS Listing
Therapeutic Area:
Multiple Sclerosis
Indication:
Clinically definite relapsing-remitting multiple sclerosis
Medical Condition:
Multiple Sclerosis
Prescriber Type:
Medical Practitioners
Restriction Type:
Authority Required (Streamlined)
Prescribing Instructions:
To be initiated by neurologists, monitoring for signs of progressive multifocal leukoencephalopathy
Comparison:
Natalizumab IV, Ofatumumab
Status:
Approved for listing
Clinical Trials:
REFINE, DELIVER
Treatment Duration:
Ongoing monitoring
Approval:
Therapeutic Goods Administration (TGA) approval on 7 December 2021
Public/Private:
Both Public and Private
Available Brands:
Tysabri
Method of Administration:
Subcutaneous injection
Intended Use:
Subcutaneous administration of natalizumab for multiple sclerosis
Safety Warnings:
Risk of progressive multifocal leukoencephalopathy